Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
BMJ Open
2023 Apr 03;134:e065613. doi: 10.1136/bmjopen-2022-065613.
Show Gene links
Show Anatomy links
Study protocol of a randomised, double-blind, placebo-controlled, two-arm parallel-group, multi-centre phase 3 pivotal trial to investigate the efficacy and safety of recombinant human alkaline phosphatase for treatment of patients with sepsis-associated acute kidney injury.
Pickkers P
,
Angus DC
,
Arend J
,
Bellomo R
,
van den Berg E
,
Bernholz J
,
Bestle M
,
Broglio K
,
Carlsen J
,
Doig CJ
,
Ferrer R
,
Joannidis M
,
Francois B
,
Doi K
,
Kellum JA
,
Laterre PF
,
Liu K
,
Mehta RL
,
Murray PT
,
Ostermann M
,
Pettilä V
,
Richards S
,
Young P
,
Zarbock A
,
Kjølbye AL
.
???displayArticle.abstract???
INTRODUCTION: Sepsis, the leading cause of acute kidney injury (AKI), is associated with a high morbidity and mortality. Alkaline phosphatase (ALP) is an endogenous detoxifying enzyme. A recombinant human ALP compound, ilofotase alfa, showed no safety or tolerability concerns in a phase 2 trial. Renal function improvement over 28 days was significantly greater in the ilofotase alfa group. Moreover, a significant relative reduction in 28-day all-cause mortality of >40% was observed. A follow-up trial has been designed to confirm these findings.
METHODS AND ANALYSIS: This is a phase 3, global, multi-centre, randomised, double-blind, placebo-controlled, sequential design trial in which patients are randomly assigned to either placebo or 1.6 mg/kg ilofotase alfa. Randomisation is stratified by baseline modified Sequential Organ Failure Assessment (mSOFA) score and trial site. The primary objective is to confirm the survival benefit with ilofotase alfa by demonstrating a reduction in 28-day all-cause mortality in patients with sepsis-associated AKI requiring vasopressors. A maximum of 1400 patients will be enrolled at ∼120 sites in Europe, North America, Japan, Australia and New Zealand. Up to four interim analyses will take place. Based on predefined decision rules, the trial may be stopped early for futility or for effectiveness. In addition, patients with COVID-19 disease and patients with 'moderate to severe' chronic kidney disease are analysed as 2 separate cohorts of 100 patients each. An independent Data Monitoring Committee evaluates safety data at prespecified intervals throughout the trial.
ETHICS AND DISSEMINATION: The trial is approved by relevant institutional review boards/independent ethics committees and is conducted in accordance with the ethical principles of the Declaration of Helsinki, guidelines of Good Clinical Practice, Code of Federal Regulations and all other applicable regulations. Results of this study will determine the potential of ilofotase alfa to reduce mortality in critically ill patients with sepsis-associated AKI and will be published in a peer-reviewed scientific journal.
TRIAL REGISTRATION NUMBER: EudraCT CT Number 2019-0046265-24. US IND Number 117 605 Pre-results.
CLINICALTRIALS: gov number: NCT04411472.
???displayArticle.pubmedLink???
37012016
???displayArticle.link???BMJ Open
Angus,
Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.
2001, Pubmed
Angus,
Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.
2001,
Pubmed
Bagshaw,
Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy.
2009,
Pubmed
Bentala,
Removal of phosphate from lipid A as a strategy to detoxify lipopolysaccharide.
2002,
Pubmed
Beumer,
Calf intestinal alkaline phosphatase, a novel therapeutic drug for lipopolysaccharide (LPS)-mediated diseases, attenuates LPS toxicity in mice and piglets.
2003,
Pubmed
Bonventre,
Cellular pathophysiology of ischemic acute kidney injury.
2011,
Pubmed
Chawla,
The severity of acute kidney injury predicts progression to chronic kidney disease.
2011,
Pubmed
Fleischmann,
Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations.
2016,
Pubmed
Gomez,
A unified theory of sepsis-induced acute kidney injury: inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury.
2014,
Pubmed
Heemskerk,
Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients.
2009,
Pubmed
Kapojos,
Induction of glomerular alkaline phosphatase after challenge with lipopolysaccharide.
2003,
Pubmed
Kellum,
Paradigms of acute kidney injury in the intensive care setting.
2018,
Pubmed
Kellum,
Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1).
2013,
Pubmed
Khundmiri,
Effect of reversible and irreversible ischemia on marker enzymes of BBM from renal cortical PT subpopulations.
1997,
Pubmed
Kiffer-Moreira,
Catalytic signature of a heat-stable, chimeric human alkaline phosphatase with therapeutic potential.
2014,
Pubmed
Koyama,
Alkaline phosphatases reduce toxicity of lipopolysaccharides in vivo and in vitro through dephosphorylation.
2002,
Pubmed
Matejovic,
Sepsis and acute kidney injury are bidirectional.
2011,
Pubmed
Oppert,
Acute renal failure in patients with severe sepsis and septic shock--a significant independent risk factor for mortality: results from the German Prevalence Study.
2008,
Pubmed
Peters,
A worldwide multicentre evaluation of the influence of deterioration or improvement of acute kidney injury on clinical outcome in critically ill patients with and without sepsis at ICU admission: results from The Intensive Care Over Nations audit.
2018,
Pubmed
Peters,
Alkaline phosphatase protects against renal inflammation through dephosphorylation of lipopolysaccharide and adenosine triphosphate.
2015,
Pubmed
Peters,
Pharmacokinetic Modeling and Dose Selection in a Randomized, Double-Blind, Placebo-Controlled Trial of a Human Recombinant Alkaline Phosphatase in Healthy Volunteers.
2016,
Pubmed
Picher,
Ecto 5'-nucleotidase and nonspecific alkaline phosphatase. Two AMP-hydrolyzing ectoenzymes with distinct roles in human airways.
2003,
Pubmed
Pickkers,
Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial.
2012,
Pubmed
Pickkers,
Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury: A Randomized Clinical Trial.
2018,
Pubmed
Rudd,
Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study.
2020,
Pubmed
Singer,
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).
2016,
Pubmed
Su,
Beneficial effects of alkaline phosphatase in septic shock.
2006,
Pubmed
Vaara,
Fluid overload is associated with an increased risk for 90-day mortality in critically ill patients with renal replacement therapy: data from the prospective FINNAKI study.
2012,
Pubmed
Verma,
Renal endothelial injury and microvascular dysfunction in acute kidney injury.
2015,
Pubmed
Verweij,
Protection against an Escherichia coli-induced sepsis by alkaline phosphatase in mice.
2004,
Pubmed
Vincent,
Sepsis in European intensive care units: results of the SOAP study.
2006,
Pubmed
Wen,
Pathogenesis of acute kidney injury: effects of remote tissue damage on the kidney.
2011,
Pubmed
Wy,
Prophylactic treatment of endotoxic shock with monophosphoryl lipid A in newborn rats.
2000,
Pubmed